{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:48:09Z","timestamp":1692506889246},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,8,15]]},"DOI":"10.2169\/internalmedicine.1282-22","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T22:11:41Z","timestamp":1673475101000},"page":"2299-2300","source":"Crossref","is-referenced-by-count":0,"title":["Importance of Metronidazole in Vonoprazan-based &lt;i&gt;Helicobacter pylori&lt;\/i&gt; Treatment in Japan"],"prefix":"10.2169","volume":"62","author":[{"given":"Sho","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Gotoda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Adachi K, Kato S, Koshino A, et al. A vonoprazan, clarithromycin, and metronidazole regimen as <i>Helicobacter pylori<\/i> eradication therapy for patients with penicillin allergy in light of clarithromycin-resistance. Intern Med 62: 2301-2306, 2023.","DOI":"10.2169\/internalmedicine.0789-22"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for <i>Helicobacter pylori<\/i> eradication. Intern Med 59: 153-161, 2020.","DOI":"10.2169\/internalmedicine.2521-18"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kato M, Ota H, Okuda M, et al. Guidelines for the management of <i>Helicobacter pylori<\/i> infection in Japan: 2016 Revised Edition. Helicobacter 24: e12597, 2019.","DOI":"10.1111\/hel.12597"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sue S, Suzuki N, Shibata W, et al. First-line <i>Helicobacter pylori<\/i> eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin. Gastroenterol Res Pract 2017: 2019802, 2017.","DOI":"10.1155\/2017\/2019802"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of <i>Helicobacter pylori<\/i> eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 22: e12374, 2017.","DOI":"10.1111\/hel.12374"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Horie R, Handa O, Ando T, et al. <i>Helicobacter pylori<\/i> eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter 25: e12698, 2020.","DOI":"10.1111\/hel.12698"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kasai T, Suzuki S, Kusano C, et al. High body mass index is correlated with the success of vonoprazan-based second-line therapy for <i>Helicobacter pylori<\/i> infection. Tohoku J Exp Med 253: 85-94, 2021.","DOI":"10.1620\/tjem.253.85"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in <i>Helicobacter pylori<\/i>: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 155: 1372-1382.e1317, 2018.","DOI":"10.1053\/j.gastro.2018.07.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for <i>Helicobacter pylori<\/i> infection in the United States and Europe: randomized clinical trial. Gastroenterology 163: 608-619, 2022.","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line <i>Helicobacter pylori<\/i> treatment: a multicentre randomised trial in Japan. Gut 69: 1019-1026, 2020.","DOI":"10.1136\/gutjnl-2019-319954"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for <i>H. pylori<\/i> infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol 55: 969-976, 2020.","DOI":"10.1007\/s00535-020-01709-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/16\/62_1282-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:21:45Z","timestamp":1692415305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/16\/62_1282-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":11,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1282-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"article-number":"1282-22"}}